Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#121 / 200 Total
EFSH - 1847 Holdings LLC - Stock Price Chart
TickerEFSH [AMEX]
Company1847 Holdings LLC
CountryUSA
IndustryConglomerates
Market Cap14.60MEPS (ttm)-131.90
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y6.75%
P/S0.21EPS next 5Y-
P/B-EPS Q/Q81.76%
Dividend-Sales Q/Q59.19%
Insider Own9.33%Inst Own0.27%
Insider Trans0.00%Inst Trans1.99%
Short Float1.23%Earnings-
Analyst Recom-Target Price-
Avg Volume259.17K52W Range1.05 - 169.00
May-06-24 08:00AM 1847 Re-Engages ShareIntel to Investigate Potentially Improper and Illegal Trading Activity in the Companys Common Stock (ACCESSWIRE) +6.98%
Apr-29-24 08:00AM 1847 Provides Update on the Sale of 1847 Cabinets Inc. (ACCESSWIRE)
Apr-23-24 08:30AM 1847 Executes Letter of Intent to Sell 1847 Cabinets Inc. for $27.6 Million (ACCESSWIRE) +17.92%
Apr-17-24 08:30AM 1847 Reports 59.2% Increase in Revenue to $15.1 Million for the Fourth Quarter of 2023 (ACCESSWIRE) -20.60%
Apr-08-24 08:00AM 1847 Holdings to Acquire a Commercial Cabinet, Door & Millwork Manufacturer with Revenues of $28.6 Million and $5.2 Million of EBITDA in 2023 (ACCESSWIRE) -10.62%
Mar-26-24 04:05PM 1847 Reminds Shareholders to Visit the Company's Website to Receive Schedule K-1 Electronically (ACCESSWIRE) -5.56%
09:30AM 1847 Holdings Request for Withdrawal of Registration Statement on Form S-3 (ACCESSWIRE)
Mar-20-24 11:30AM INTERVIEW: Benzinga Sits Down With Diversified Holding Company 1847's (NYSE: EFSH) CEO To Discuss The Company's Wins, Its Strategies For Success And More (ACCESSWIRE) +27.48%
Mar-13-24 10:00AM 1847 Holdings' ICU Eyewear Subsidiary Diversifies Manufacturing to Reduce Production Costs and Fortify Supply Chain (ACCESSWIRE) -46.92%
Mar-12-24 10:30AM Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE) +13.04%
NGNE - Neurogene Inc - Stock Price Chart
TickerNGNE [NASD]
CompanyNeurogene Inc
CountryUSA
IndustryBiotechnology
Market Cap421.61MEPS (ttm)-1.91
P/E-EPS this Y-231.77%
Forward P/E-EPS next Y6.13%
PEG-EPS past 5Y-16.09%
P/S-EPS next 5Y25.10%
P/B2.26EPS Q/Q-283.53%
Dividend-Sales Q/Q-
Insider Own10.43%Inst Own61.84%
Insider Trans0.00%Inst Trans-32.57%
Short Float8.58%EarningsMar 18/a
Analyst Recom1.00Target Price51.50
Avg Volume135.10K52W Range12.20 - 53.00
Apr-22-24 04:36PM Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire)
Mar-04-24 07:30AM Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%
GNPX - Genprex Inc - Stock Price Chart
TickerGNPX [NASD]
CompanyGenprex Inc
CountryUSA
IndustryBiotechnology
Market Cap5.49MEPS (ttm)-22.93
P/E-EPS this Y74.42%
Forward P/E-EPS next Y51.82%
PEG-EPS past 5Y8.89%
P/S-EPS next 5Y-
P/B0.52EPS Q/Q29.18%
Dividend-Sales Q/Q-
Insider Own3.22%Inst Own5.77%
Insider Trans0.00%Inst Trans27.43%
Short Float2.45%Earnings-
Analyst Recom1.00Target Price10.00
Avg Volume82.11K52W Range2.09 - 42.40
May-01-24 08:31AM Genprex to Present and Participate at Upcoming May Investor and Industry Conferences (PR Newswire)
Apr-09-24 08:31AM Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 08:57AM Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up (Zacks)
Apr-03-24 08:31AM Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +9.51%
Apr-02-24 08:31AM Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System (PR Newswire)
Mar-22-24 04:10PM Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Mar-19-24 01:24PM Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.36%
Mar-12-24 09:01AM Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers (PR Newswire) -10.43%
Mar-06-24 08:30AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire) +6.31%
Feb-07-24 08:15AM Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators (PR Newswire) -11.17%
GMM - Global Mofy Metaverse Ltd - Stock Price Chart
TickerGMM [NASD]
CompanyGlobal Mofy Metaverse Ltd
CountryChina
IndustryInformation Technology Services
Market Cap27.40MEPS (ttm)0.25
P/E4.00EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.02EPS next 5Y-
P/B1.25EPS Q/Q1000.78%
Dividend-Sales Q/Q136.33%
Insider Own64.54%Inst Own2.45%
Insider Trans0.00%Inst Trans-
Short Float1.80%Earnings-
Analyst Recom-Target Price-
Avg Volume1.77M52W Range0.65 - 15.47
Apr-30-24 10:50AM Why Is Global Mofy Metaverse (GMM) Stock Up 52% Today? (InvestorPlace) +59.09%
08:00AM Global Mofy Metaverse and Heartdub Leverage NVIDIA Omniverse to develop Generative Video AI Platform GAUSSPEED (GlobeNewswire)
Apr-24-24 08:00AM One of China's Leading Content Creators Selects Global Mofy for Upcoming TV Show (GlobeNewswire)
Apr-11-24 08:30AM Alert: Global Mofy Officially Adopts OpenUSD as Digital Asset Development Standard (GlobeNewswire)
Apr-02-24 08:30AM Global Mofy Featured at China's 2024 Fashion Week; Highlights Convergence of Digitized Fashion, AI and the Metaverse (GlobeNewswire)
Mar-25-24 08:30AM Global Mofy Metaverse Explores Partnership to Integrate Metaverse and AI Technology with Traditional Chinese and Western Therapeutic Practices (GlobeNewswire) +12.22%
Mar-11-24 08:30AM Global Mofy Metaverse Announces New Subsidiary for AI Technology Monetization and Synthetic Video Content Creation (GlobeNewswire) +30.69%
Mar-04-24 09:00AM Global Mofy Metaverse Wins Major New Customer Order (GlobeNewswire) -18.50%
Jan-31-24 10:06AM /C O R R E C T I O N -- Global Mofy Metaverse Limited/ (PR Newswire) -13.15%
08:30AM Global Mofy Metaverse Reports Record 2023 Financial Year Results (PR Newswire)
CTMX - CytomX Therapeutics Inc - Stock Price Chart
TickerCTMX [NASD]
CompanyCytomX Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap297.77MEPS (ttm)-0.02
P/E-EPS this Y-4286.00%
Forward P/E-EPS next Y-10.92%
PEG-EPS past 5Y67.21%
P/S2.94EPS next 5Y-0.90%
P/B-EPS Q/Q109.36%
Dividend-Sales Q/Q32.22%
Insider Own1.84%Inst Own47.89%
Insider Trans-5.69%Inst Trans-20.06%
Short Float5.37%EarningsMay 08/a
Analyst Recom2.57Target Price3.95
Avg Volume4.63M52W Range1.04 - 5.85
May-06-24Upgrade Jefferies Hold → Buy $2.50 → $8
May-06-24 07:09AM Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8 (MT Newswires)
May-02-24 08:08AM CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? (Zacks) -12.28%
07:37AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-01-24 12:11PM Cannabis Stocks CGC, ACB, TLRY Drop After Huge Rescheduling Rally (InvestorPlace) +214.72%
11:43AM Why Is CytomX (CTMX) Stock Up 180% Today? (InvestorPlace)
08:00AM CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors (GlobeNewswire)
Apr-03-24 08:00AM CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
Mar-21-24 08:00AM CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors (GlobeNewswire)
Mar-18-24 08:00AM CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas (GlobeNewswire)
BOWL - Bowlero Corp - Stock Price Chart
TickerBOWL [NYSE, RUT]
CompanyBowlero Corp
CountryUSA
IndustryLeisure
Market Cap1.68BEPS (ttm)0.19
P/E59.04EPS this Y-129.26%
Forward P/E31.21EPS next Y508.86%
PEG-EPS past 5Y-
P/S1.54EPS next 5Y-
P/B-EPS Q/Q-5100.00%
Dividend0.49%Sales Q/Q11.81%
Insider Own44.45%Inst Own68.18%
Insider Trans-0.19%Inst Trans-2.12%
Short Float16.68%EarningsMay 06/b
Analyst Recom1.00Target Price19.15
Avg Volume884.20K52W Range8.85 - 15.47
May-06-24 01:53PM BOWL Stock Earnings: Bowlero Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace) -10.33%
07:30AM Bowlero Reports Third Quarter Results for Fiscal Year 2024 (Business Wire)
Apr-29-24 10:00AM Analysts Estimate Bowlero Corp. (BOWL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-22-24 05:00PM Bowlero to Report Third Quarter 2024 Financial Results on May 6, 2024 (Business Wire)
Apr-09-24 03:32PM Former Bowlero exec says company threatened to report him to FBI (CNBC TV)
Mar-28-24 09:00AM Bowlero Promotes Zac Sulma to Chief Sales Officer (Business Wire)
Mar-26-24 07:49AM 20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
Mar-25-24 08:00AM Bowlero Corp. Opens Lucky Strike Miami (Business Wire)
Feb-06-24 10:40AM Bowlero (BOWL) Q2 Earnings Miss Estimates, Revenues Surpass (Zacks)
08:51AM Bowlero Corp. (NYSE:BOWL) Q2 2024 Earnings Call Transcript (Insider Monkey)
LTRN - Lantern Pharma Inc - Stock Price Chart
TickerLTRN [NASD]
CompanyLantern Pharma Inc
CountryUSA
IndustryBiotechnology
Market Cap73.71MEPS (ttm)-1.47
P/E-EPS this Y-38.32%
Forward P/E-EPS next Y7.38%
PEG-EPS past 5Y-39.81%
P/S-EPS next 5Y-
P/B1.80EPS Q/Q-24.47%
Dividend-Sales Q/Q-
Insider Own26.83%Inst Own10.55%
Insider Trans-19.44%Inst Trans0.92%
Short Float6.32%EarningsMay 09/a
Analyst Recom2.00Target Price22.00
Avg Volume329.59K52W Range2.38 - 11.99
May-06-24 06:41AM Lantern Pharma and Oregon partner to develop cancer treatment (Pharmaceutical Technology) +11.38%
04:37AM Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration (MT Newswires)
03:00AM Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism (Business Wire)
May-02-24 07:30AM Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
May-01-24 06:00AM 3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
PALI - Palisade Bio Inc - Stock Price Chart
TickerPALI [NASD]
CompanyPalisade Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap7.19MEPS (ttm)-28.25
P/E-EPS this Y46.67%
Forward P/E-EPS next Y-19.79%
PEG-EPS past 5Y75.28%
P/S28.76EPS next 5Y-
P/B0.46EPS Q/Q76.46%
Dividend-Sales Q/Q-
Insider Own1.75%Inst Own2.09%
Insider Trans201.68%Inst Trans-
Short Float4.11%EarningsMar 27/b
Analyst Recom1.00Target Price22.50
Avg Volume1.11M52W Range3.82 - 36.60
May-02-24 08:30AM Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-01-24 08:30AM Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) (GlobeNewswire) +17.41%
Apr-23-24 08:30AM Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach (GlobeNewswire) +20.08%
Apr-16-24 11:22AM Why Is Palisade Bio (PALI) Stock Up 57% Today? (InvestorPlace) +42.55%
08:30AM Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool (GlobeNewswire)
Apr-11-24 09:15AM Palisade Bio to Participate in the Virtual Investor Lunch Break Event (GlobeNewswire) +7.62%
Apr-10-24 08:15AM Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis (GlobeNewswire) -24.91%
Apr-03-24 05:30PM Palisade Bio Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Mar-27-24 08:00AM Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +6.04%
Mar-26-24 11:52PM PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023 (InvestorPlace)
CTNM - Contineum Therapeutics Inc. - Stock Price Chart
TickerCTNM [NASD]
CompanyContineum Therapeutics Inc.
CountryUSA
IndustryBiotechnology
Market Cap372.43MEPS (ttm)-
P/E-EPS this Y-3827.78%
Forward P/E-EPS next Y2.68%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own43.40%Inst Own13.08%
Insider Trans0.00%Inst Trans-
Short Float3.68%Earnings-
Analyst Recom1.00Target Price28.00
Avg Volume158.24K52W Range13.65 - 16.06
Apr-04-24 09:02PM Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
UGRO - Urban-gro Inc - Stock Price Chart
TickerUGRO [NASD]
CompanyUrban-gro Inc
CountryUSA
IndustryFarm & Heavy Construction Machinery
Market Cap23.28MEPS (ttm)-1.37
P/E-EPS this Y72.44%
Forward P/E-EPS next Y42.08%
PEG-EPS past 5Y-13.77%
P/S0.33EPS next 5Y20.00%
P/B1.25EPS Q/Q62.88%
Dividend-Sales Q/Q-7.29%
Insider Own33.73%Inst Own25.08%
Insider Trans-0.02%Inst Trans7.66%
Short Float2.78%EarningsApr 30/a
Analyst Recom1.00Target Price4.64
Avg Volume115.45K52W Range1.00 - 2.84
May-01-24 10:45AM urban-gro, Inc. (NASDAQ:UGRO) Q1 2024 Earnings Call Transcript (Insider Monkey) -11.00%
Apr-30-24 08:57PM UGRO Stock Earnings: Urban-gro Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +18.08%
04:05PM urban-gro, Inc. Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance (ACCESSWIRE)
Apr-18-24 04:30PM 7 Small-Cap Gems Under $10 Primed for 1,000% Growth (InvestorPlace)
Apr-15-24 08:30AM urban-gro, Inc. to Report First Quarter 2024 Financial Results on April 30, 2024 (ACCESSWIRE)
Apr-01-24 05:14PM urban-gro, Inc. (NASDAQ:UGRO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 08:39AM Why Is Urban-gro (UGRO) Stock Down 18% Today? (InvestorPlace) -24.52%
Mar-27-24 08:53PM UGRO Stock Earnings: Urban-gro Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.92%
04:05PM urban-gro, Inc. Reports 2023 Financial Results and Provides Outlook on 2024 Performance (ACCESSWIRE)
Mar-13-24 08:00AM urban-gro, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 27, 2024 (ACCESSWIRE) +6.12%
1⋯89101112131415161718⋯20
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.